

Dr. Paul J. Shaughnessy's Publications

Book Chapters:

1. Shaughnessy PJ, LeMaistre CF. "DAB₃₈₉IL-2 (ONTAK): "Development and Therapeutic Applications". In: Kwakami K, Aggarwak B, Puri R, eds. *Cytotoxins and Immunotoxins for Cancer Therapy: Clinical Applications*. CRC Press, 115:2005.

Journal Articles:

1. LeMaistre JA, Bachier C, Smith B, LeMaistre CF, **Shaughnessy PJ**. Once daily Busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant. *J Oncol Pharm Pract*. 2011 Jan 12
2. Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers ME, Gupta V, Hsu JW, Jagasia M, Kitko CL, Maziarz RT, Rowley SD, **Shaughnessy PJ**, Van Besien K, Weisdorf D, Lee SJ. Comparison between short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. *Biol Blood Marrow Transplant* 2011 Jan; 17(1):124-32 Epub 2010 Jun 30
3. **Shaughnessy P**, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweeney PA. Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor compared to G-CSF and Cyclophosphamide. *Biol Blood Marrow Transplant* 2010 Aug 30
4. **Shaughnessy PJ**, Bolwell BJ, van Besien K, Mistrik, M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Rogers J, Gallo J, Foss F, Apperley J, Zhang M, Horowitz M, Abhyankar, S. Extracorporeal Photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplantation*. Epub. November 2009.
5. Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, **Shaughnessy PJ**, DeVetten MP, Jagasia M, Fay JW, van Besien, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. *Blood*. 113(21): 5074-5082, May 2009.
6. Gazitt Y, **Shaughnessy P**, Rothenber ML. A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients. *Oncology Rep*. 16(4): 877-84, Oct 2006.
7. **Shaughnessy PJ**, Bachier C, LeMaistre C, Akay C, Pollock, BH, Gazitt Y. Granulocyte Colony-Stimulating Factor Mobilizes More Dendritic Cell Subsets Than Granulocyte-macrophage Colony-Stimulating Factor with No Polarization of Dendritic Cell Subsets in Normal Donors. *Stem Cells*. 24(7):1789-1797, July 2006.
8. Coureil D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banocloche J, **Shaughnessy PJ**, et al. MED. Ancillary therapy and Supportive Care of Chronic Graft-Versus-Host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: V. Ancillary Therapy and Supportive Care working Group Report. *Biology of Blood and Marrow Transplantation*. 12(4): 375-396, Apr 2006.

9. **Shaughnessy PJ**, Alexander W, Tran H, Ririe D, Splichal J, Pollack M, Bachier C, LeMaistre CF. Phase I and Pharmacokinetic Study of Once Daily Dosing of Intravenous Busulfan in the Setting of a Reduced Intensity Preparative Regimen and Allergenic Hematopoietic Stem Cell Transplantation as Immunotherapy for Renal Cell Carcinoma. *Mil Med.* 171(2): 161-165, Feb 2006.
10. Shaughnessy PJ, Bachier C, Grimley M, Freytes C, Callander N, Essell J, Flomenber N, Selby G, LeMaistre, CF. Denileukin Diftitox for the Treatment of Steroid-Resistant Acute Graft vs. Host Disease. *Biology of Blood and Marrow Transplantation.* 11(3):188-193, Mar 2005.
11. Ornstein DL, Frye BL, Ririe D, Shaughnessy P, Burke CT, Coronado I. Allogeneic Hematopoietic Stem Cell Transplantation in the Active Duty Military Population: 1987-2001. *Mil Med.* 168(1):28-31. Jan 2003.
12. Shaughnessy PJ, Ornstein D, Ririe D, Callander N, Anderson JE, Pollack MS, Freytes CO, Cruz J, Rodriguez T, Bachier C, LeMaistre CF. Phase II Study of a Moderate Intensity Preparative Regimen with Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Diseases: The Texas Transplant Consortium Experience. *Biology of Blood and Marrow Transplantation.* 8:420-8, 2002.
13. Gazitt Y, Shaughnessy PJ, Liu Q. Expression of adhesion molecules on CD34+ cells in peripheral blood of non-Hodgkin's lymphoma patients mobilized with different growth factors. *Stem Cells.* 19(2):134-43, 2001.
14. Kovitz CA, Bickford D, Ornstein DL, Ririe DW, Shaughnessy PJ, Fischer J. Allogeneic bone marrow transplantation at Wilford Hall USAF Medical Center: 1987-1999. *Military Medicine.* 166(12):1049-53, 2001.
15. Ornstein DL, Ririe DW, Shaughnessy PJ, Neuhauser T, Bee C. Nonmyeloablative allogeneic peripheral blood stem cell transplantation for multifocal extramedullary plasmacytomas progressing after autologous transplantation. *Bone Marrow Transplantation.* 29:71-74, 2001.
16. Ornstein D, Mortara K, Smith M, Ririe D, Shaughnessy PJ, Bickford D, Kissack B. Treatment of severe thrombocytopenia in alloimmunized, transfusion refractory patients. *Military Medicine.* 166:269-274, 2001.
17. Shaughnessy PJ, Ririe D, Ornstein D, Kissack B, Bickford D, Molina R, Lanzkron S, Bachier C, Nanez A, LeMaistre CF. Graft failure in a patient with systemic lupus erythematosus treated with high dose immunosuppression and autologous stem cell rescue. *Bone Marrow Transplantation.* 27:221-224, 2001.
18. Gazitt Y, Shaughnessy PJ, Devore P. Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. *Journal of Hematotherapy and Stem Cell Research.* 10:177-186, 2001.
19. Gazitt Y, Shaughnessy PJ, Liu Q. Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. *Journal of Hematotherapy and Stem Cell Research.* 10:167-176, 2001.
20. Shaughnessy PJ, Kissack B, Bickford D, Ririe D, Lopez JD, Hensley R, Smith R, Schroeder M. Correlation of CD34+ percentage with volume of bone marrow collected for allogeneic bone marrow harvests. *Journal of Hematotherapy and Stem Cell Research.* 9:891-894, 2000.

21. Gazitt Y, Callander N, Freytes C, Shaughnessy PJ, Liu Q, Tsai T, Devore P. Peripheral. Blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: A randomized study. *Journal of Hematotherapy and Stem Cell Research*. 9:737-748, 2000.
22. Gazitt Y, Shaughnessy PJ, Montgomery W. Apoptosis-induced by trail and TNF-alpha in human multiple myeloma cells are not blocked by BCL-2. *Cytokine*. 11:1010-1019, 1999.

Abstracts:

1. Potter G.W., LeMaistre, C.F., Shaughnessy, P., Islas, M., Huerta, J. Bachier, C. Collection of Autologous Peripheral Blood Stem Cells Using the COBE Spectra is Associated with Higher CD34+ Yields and Requires Less Collection Time than the Fresenius AS104 Cell Separator. *Blood*. 114(22): 848, 2009.
2. Shaughnessy, P., Islas-Ohlmayer, M., Murphy, J., Hougham, M., MacPherson, J., Winkler, K., Silva, M., Steinberg, M., Matous, J., Selvey, S., Maris, M., McSweeney, P.A. Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization. *Blood*. 114(22): 897-898, 2009.
3. Micallef, I., Jacobsen, E., Shaughnessy, P., Marulkar, S., Mody, P., van Rhee, F. Plerixafor (Mozobil) Plus G-CSF is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation. *Blood*. 114(22): 1251, 2009.
4. Delgado E, LeMaistre CF, Bachier C, Smith B, Lopez-Gonzalez G, Hougham M, Kaleel S, Shaughnessy P. Cost analysis of mobilization and autologous transplantation in patients who received AMD3100 after failing standard mobilization. *Biology of Blood and Marrow Transplantation*. 15(2) Suppl 2: 248, 2009.
5. Lopez-Gonzalez G, LeMaistre CF, Bachier C, Smith B, Chan KW, Grimley M, Cain W, Delgado E, Kaleel S, Shaughnessy P. Clinical and cost outcomes of double umbilical cord blood versus bone marrow and peripheral blood unrelated donor hematopoietic stem cell transplants. *Biology of Blood and Marrow Transplantation*. 14(2) Suppl 2: 277, 2009.
6. LeMaistre, J., Bachier, C., Smith, B., LeMaistre, C.F., Shaughnessy, P.J. Once Daily Busulfan Cyclophosphamide is Well-Tolerated and Effective Prior to Allogeneic Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*. 14(2) Supple2: 111, 2008.
7. Potter, G.W., Bachier, C., Smith B., Houghman, M., LeMaistre, C.F., Shaughnessy, P.J. Once Daily Busulfan and Fludarabine is Well-Tolerated and Effective in Older Heavily Treated Patients Prior to Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplant. *Biology of Blood and Marrow Transplantation*. 14(2) Supple 2: 120, 2008.
8. Bachier, C.R., Shaughnessy, P., Smith, B., Salinas, R., LeMaistre, C.F. Immune Activation with Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor for Treatment of Relapse after Allogeneic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*. 14(2) Supple 2: 131-32, 2008.

9. Lopez-Gonzalez, G., LeMaistre, C.F., Bachier, B., Smith, B., Chan, K.W., Grimley, M., Cain, W., Delgado, E., Kaleel, S., Shaughnessy, P. Clinical and Cost Outcomes of Double Umbilical Cord Blood Versus Bone Marrow and Peripheral Blood Unrelated Hematopoietic Stem Cell Transplants. *Blood*. 112(11): 355-56, 2008.
10. Delgado, E., LeMaistre, C.F., Bachier, C., Smith, B., Lopez-Gonzalez, G., Houghman, M., Kaleel, S., Shaughnessy, P. Cost Analysis of Mobilization and Autologous Transplantation in Patients Who Received AMD 3100 after Failing Standard Mobilization. *Blood* 112(11): 749-50, 2008.
11. Bachier, C.R., Shaughnessy, P, Smith, B., Salinas, R., LeMaistre, C.F., Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor is an Alternative to Donor Lymphocyte Infusion for Relapse after Allogeneic Stem Cell Transplantation and is Associated with Increase Immune Effector Cells and Polarization to Type 2 Dendritic Cells. 2007 ASH Annual Meeting Abstracts in Atlanta, GA. *Blood*. 11(1) 110: 2007 Abstract 1647.
12. LeMaistre, J., Bachier, C., Smith, B., LeMaistre, C.F., Shaughnessy, P.J. Once Daily Busulfan Cyclophosphamide is Well Tolerated and Effective Prior to Allogeneic Hematopoietic Stem Cell Transplantation. 2007 ASH Annual Meeting Abstracts in Atlanta, GA. *Blood*. 11(1) 110: 2007 Abstract 1996.
13. Potter, G.W., Bachier, C., Smith, B., Houghman, M., LeMaistre, C.F., Shaughnessy, P.J. Once Daily Busulfan and Fludarabine is Well-Tolerated and Effective in Older Heavily Treated Patients Prior to Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplant. 2007 ASH Annual Meeting Abstracts in Atlanta, GA. *Blood*. 11(2) 110: 2007 Abstract 4950.
14. Bachier, C.R., Shaughnessy, P., Wall, D., Grimley, M., LeMaistre, C.F. Interleukin-2 (IL-2) and Granulocyte-Macrophage Stimulation Factor (GM-CSF) for Treatment of Relapse after Allogeneic Stem Cell Transplant (ASCT). 2006 BMT Tandem Meeting in Honolulu, HI. *Biology of Blood and Marrow Transplantation*. 12(2):56, Feb. 2006 Abstract 157.
15. Aberle, M.F., Bachier, C., LeMaistre, F.C, Shaughnessy, P.J. Valganciclovir is Effective in the Preemptive Treatment of Cytomegalovirus (CMV) Infection after Allogeneic Stem Cell Transplant (ASCT). 2006 BMT Tandem Meeting in Honolulu, HI. *Biology of Blood and Marrow Transplantation*. 12(2): 136, Feb. 2006 Abstract 392.
16. Hoerster, C.M., Bachier, C., LeMaistre, C.F., Shaughnessy, P. Descriptive Analysis on the Role and Outcomes of Psychological Evaluation and Intervention in Patients Undergoing Stem Cell Transplant. 2006 BMT Tandem Meeting in Honolulu, HI. *Biology of Blood and Marrow Transplantation*. 12(2): 142, Feb. 2006 Abstract 408.
17. Shaughnessy PJ, Bachier C, Alexander L, Bowen B, LeMaistre CF. Intravenous busulfan dosed four times daily or once daily as part of the standard BuCy preparative regimen for allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*. 11(2):28. 2005.
18. Abhyankar S, Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Machado A, Thienel U, Wang J, Foss F, Apperley J. A multi-institutional study of extracorporeal photoimmune therapy (ECP) with UVADEX® for the prevention of acute GVHD in patients (pts) undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation (AHCT). *Biology of Blood and Marrow Transplantation*. 11(2):37.

19. Bachier C, Shaughnessy P, Wall D, Grimley M, Carrum G, Freytes C, Callander N, Walsh T, LeMaistre CF. Valganciclovir for the prophylaxis of early cytomegalovirus (CMV) infection after allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*. 11(2):90-91. 2005.
20. Walsh TL, Bachier C, Shaughnessy P, Freytes CO, Callander N, LeMaistre CF, Grimley M, Bradshaw P. Efficacy of fluconazole prophylaxis for autologous peripheral blood stem cell transplantation: Results of a prospective, randomized, controlled, multi-center, open label study. *Biology of Blood and Marrow Transplantation*. (11)2:106. 2005.
21. Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Callander NS, Essell JH, Flomenberg N, Selby G, Lemaistre CF. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. *Biology of Blood and Marrow Transplantation*. 11(3):188-193. 2005.
22. Shaughnessy PJ, Bachier C, Wall D, Grimley M, Carrum G, Freytes C, Callander N, Walsh T, LeMaistre CF. Valganciclovir for the Early Prophylaxis of Cytomegalovirus (CMV) Infection after Allogeneic Stem Cell Transplantation. *Blood*. 104(11):2004. Abstract 5074.
23. Shaughnessy PJ, Walsh T, Bachier C, Freytes C, Callander N, LeMaistre CF, Grimley M, Bradshaw P. Efficacy of Fluconazole Prophylaxis for Autologous Peripheral Blood Stem Cell Transplantation: Results of a Prospective, Randomized, Controlled, Multi-center, Open Label Study. *Blood*. 104(11):2004. Abstract 5096.
24. Shaughnessy PJ, Bachier C, Nanez A, Akay C, LeMaistre CF, Gazitt Y. Comparison between G-CSF and GM-CSF for Mobilization of Dendritic Cells, CD34+ Cells, and CD3+ Cells, and CD3+ Cells in Normal Donors. *Blood*. 104(11):785a, 2004. Abstract 2870.
25. Shaughnessy PJ, Bolwell BJ, van Besien K, Abhyankar S, Mistrik M, Ilhan O, Grigg A, Prince HM, Dodds T, Machado A, Gruben D, Thienel U, Foss F, Apperley J. A Multi-Institutional Study of Extracorporeal Photoimmune Therapy with Uvadex[®] for the Prevention of Acute GvHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*. 104(11):347a, 2004. Abstract 1230.
26. Shaughnessy PJ, Bolwell BJ, van Besien K, Abhyankar S, Mistrik M, O. Ilhan, Grigg A, Prince HM, Dodds T, Machado A, Gruben D, Thienel U, Foss F, Apperley J. Extracorporeal Photoimmune Therapy with Uvadex[®] for the Prevention of Acute Graft vs. Host Disease in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation. *Bone Marrow Transplantation*. 33(Sup. 1):S189, 2004. Abstract P727.
27. Shaughnessy PJ, Bachier C, Freytes C, Callander N, Essell J, Grimley M, LeMaistre CF. Phase II Study of Denileukin Diftitox (Ontak[®]) for Treatment of Steroid Resistant Acute Graft Versus Host Disease. *Blood* 102(11):715a, 2003.
28. Shaughnessy PJ, Bolwell BJ, Abhyankar S, van Besien K, Mistrik M, Grigg A, Dodds A, Machado A, Gruben D, Thienel U. Extracorporeal Photoimmune Therapy with Uvadex[®] for the Prevention of Acute Grave versus Host Disease in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*. 102(11):714a, 2003.
29. Shaughnessy PJ, Bachier C, Grimley M, LeMaistre CF. Phase II Study of Denileukin Diftitox (Ontak[®]) in the Treatment of Steroid Resistant Acute Graft vs. Host Disease (AGVHD). *Biology of Blood and Marrow Transplantation*. 9(2):98, 2003.

30. Trevino A, Shaughnessy PJ, Hudak P, Lanzkron S, Bachier C, LeMaistre CF. Digene Hybrid Capture (DHC) CMV DNA Assay Compared to CMV Culture and Incidence of CMV Disease in Allogeneic Hematopoietic Stem Cell Transplantation (ASCT). *Biology of Blood and Marrow Transplantation*. 9(2):137, 2003.
31. Shaughnessy PJ, Bachier C, Long L, LeMaistre CF, Gazitt Y. Comparison between G-CSF and GM-CSF for mobilization of dendritic cells, CD34+ cells, and CD3+ cells in normal donors. *Blood*. 100(11):827a, 2002. LeMaistre CF, Bachier C, Cloud RS, Cayce K, Alexander L, Wall DA, Gonzales B, Shaughnessy PJ. Both Charges and Reimbursement for Reduced Intensity Preparative Regimens (RIR) Are Comparable to Myeloablative Regimens (MR) in Matched Related Allogeneic Stem Cell Transplant (ASCT). ASBMT 2002. *Biology of Blood and Marrow Transplantation*. 8(2):79-80, 2002.
33. Heller BJ, Ornstein DL, Hensley R, Ririe DW, Shaughnessy PJ, Bee C, Reilly RA. Predicting Successful Peripheral Blood Stem Cell (PBSC) Collection Using Peripheral WBC and CD34+ Cell Counts: A Cost Analysis. ASBMT 2002. *Biology of Blood and Marrow Transplantation*. 8(2):2002. Abstract 138.
34. Shaughnessy PJ, Tran H, Andersson W, Sprigg-Saenz H, Splichal J, Alexander W, Ornstein D, Ririe D, Bachier C, LeMaistre CF. Pharmacokinetics (PK) of Once Daily Dosing of Intravenous Busulfan (IVBU) in a Reduced Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation (ASCT). ASBMT meeting 2002. *Biology of Blood and Marrow Transplantation*. 8(2):2002. Abstract 76.
35. LeMaistre CF, Bachier C, Cloud RS, Cayce K, Alexander L, Wall DA, Gonzales B, Shaughnessy PJ. Reduced Intensity Preparative Regimens (RIR) Offer No Cost Savings Over Myeloablative Regimens (MR) in Matched Related Allogeneic Stem Cell Transplant. American Society of Hematology 43rd Annual Meeting & Exposition, 2001. *Blood* 98(11):2001. Abstract 798.
36. Shaughnessy PJ, Tran H, Andersson B, Sprigg-Saenz H, Splichal J, Alexander W, Ornstein D, Ririe D, Bachier C, LeMaistre CF. Pharmacokinetics (PK) and Toxicity of Once Daily Dosing of Intravenous Busulfan (IVBU) in a Reduced Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation (ASCT). American Society of Hematology 43rd Annual Meeting & Exposition, 2001. *Blood* 98(11):2001. Abstract 5041.
37. Gazitt Y, Roodman D, Shaughnessy PJ. A Phase I-II trial with Gemcitabine and Paclitaxel for the treatment of refractory multiple myeloma patients. Proceedings of ASCO. 20:2001. Abstract 2686.
38. Shaughnessy PJ, Ririe D, Ornstein D. Phase I study of escalating doses of melphalan with ifosfamide, carboplatin, and etoposide (MICE) with autologous stem cell support. *Biology of Blood and Marrow Transplantation*. 7:2001 Abstract 95 (ASBMT 2001).
39. Shaughnessy PJ, Ririe D, Ornstein D, Callander N, Anderson JE, Pollack M, Freytes C, Cruz J, Rodriguez T, Bachier C, LeMaistre CF. Phase II Study of a Moderate Intensity Preparative Regimen and Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Diseases: The Texas Transplant Consortium Experience. *Blood*. 96:2001. Abstract 3389a.

40. Shaughnessy PJ, Ririe D, Raybon K, Schroeder M, Snyder M. High Dose Chemotherapy with BCNU, Cytarabine, Cyclophosphamide, and Etoposide (BACE) and Autologous Stem Cell Rescue for Relapsed Chemotherapy Sensitive Hodgkin's Disease and Non-Hodgkin's Lymphoma. Wilford Hall Medical Center. San Antonio TX. *Blood* 94(10):1999. Abstract 5042.
41. Ririe D, Shaughnessy PJ, Moore R, Ornstein D. Excellent Results in the Treatment of Severe Aplastic Anemia Using Cyclophosphamide and ATG as the Preparative Regimen in Allogeneic Bone Marrow Transplantation. Wilford Hall Medical Center. San Antonio TX. *Blood*. 94(10): 1999. Abstract 4995.
42. Shaughnessy PJ, Ririe D, Osswald M, Lewis S. High Dose Chemotherapy With BICE (BCNU, Ifosfamide, Carboplatin, and Etoposide) and Autologous Bone Marrow Transplantation for Patients With Ewings Sarcoma (ES). Wilford Hall Medical Center Bone Marrow Transplant Department, San Antonio, TX. *Blood*. 92(10), 1998. Abstract 4602.
43. Shaughnessy PJ, Lewis S, Allerton J, Shroeder M. The Bili Day Index (BDI): A Simplified Way to Predict Life Threatening Veno Occlusive Disease (VOD) in allogeneic Bone Marrow Transplant (BMT) Patients. Wilford Hall Medical Center, Lackland AFB, Texas. *Blood*. 90(10), 1997.
44. Shaughnessy PJ, Lewis S, Shroeder M, Allerton J, Wilks S, Christman K, Osswald M, Abbott K, Harmon G, Halverson R, Snyder M, Callender N. Bone Marrow Transplantation for Patients with Severe Aplastic Anemia Using Cyclophosphamide and Antithymocyte Globulin (ATG). Wilford Hall Medical Center, Lackland AFB, Texas. *Blood*. 86(10). 1996.